GlassScriptPhysician profile
Kimberly A Yeager
NPI 1669812681
$9,237.81
in general payments reported to CMS, 2019-2025
56 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,432 · 2022: $2,490 · 2023: $2,240 · 2024: $1,152 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,214.34 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,784.09 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $369.02 | 2021-2025 | Fanapt |
| Lilly USA, LLC | $352.94 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $347.35 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $335.25 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $333.14 | 2021-2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.73 | 2021-2023 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $272.69 | 2021-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $272.47 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Pfizer INC. | $271.91 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $250.40 | 2021-2023 | |
| Alkermes, INC. | $243.56 | 2024-2025 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $222.23 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $216.84 | 2021-2025 | Spravato, Invega Sustenna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.46 | 2021-2024 | Xifaxan |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Yeager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.